- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00370552
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
9. Februar 2016 aktualisiert von: R-Pharm
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer.
The study will also assess the safety of this combination treatment.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Studientyp
Interventionell
Einschreibung (Tatsächlich)
136
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Besancon Cedex, Frankreich, 25030
- Local Institution
-
Clermont-Ferrand, Frankreich, 63000
- Local Institution
-
Marseille Cedex 9, Frankreich, 13273
- Local Institution
-
Paris Cedex 10, Frankreich, 75475
- Local Institution
-
Saint Herblain, Frankreich, 44805
- Local Institution
-
Strasbourg Cedex, Frankreich, 67085
- Local Institution
-
Tours Cedex, Frankreich, 37044
- Local Institution
-
-
-
-
-
Cuneo, Italien, 12100
- Local Institution
-
Meldola Fc, Italien, 47014
- Local Institution
-
Milano, Italien, 20132
- Local Institution
-
Modena, Italien, 41100
- Local Institution
-
Napoli, Italien, 80131
- Local Institution
-
Roma, Italien, 00161
- Local Institution
-
-
-
-
-
Hospitalet De Llobregat, Spanien, 08907
- Local Institution
-
Jaen, Spanien, 23007
- Local Institution
-
-
-
-
California
-
Burbank, California, Vereinigte Staaten, 91505
- East Valley Hematology and Oncology medical Group
-
La Verne, California, Vereinigte Staaten, 91750
- Wilshire Oncology Medical Group, Inc.
-
San Francisco, California, Vereinigte Staaten, 94115
- Ucsf-Comprehensive Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa Hospitals and Clinics
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65203
- Ellis Fischel Cancer Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Weill Medical College of Cornell University
-
-
-
-
-
Merseyside, Vereinigtes Königreich, CH63 4JY
- Local Institution
-
-
Essex
-
Chelmsford, Essex, Vereinigtes Königreich, CM1 7ET
- Local Institution
-
-
Greater Manchester
-
Manchester, Greater Manchester, Vereinigtes Königreich, M20 4BX
- Local Institution
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, Vereinigtes Königreich, NG5 1PB
- Local Institution
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion criteria:
- Locally recurrent or metastatic breast cancer, previously untreated with chemotherapy for advanced disease.
- At least 1 target lesion per RECIST criteria. Locally recurrent disease must not be amenable to resection with curative intent.
- No previous cytotoxic chemotherapy for locally recurrent/metastatic disease.
- Relapse 12 months or more after completing prior adjuvant or neoadjuvant taxane therapy.
- No previous breast cancer known to overexpress or amplify the human epidermal growth factor receptor 2 gene.
- Prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization.
- Karnofsky performance status of 80 to 100 or Eastern Cooperative Oncology Group performance status of 0 to 1.
- Estimated life expectancy of at least 12 weeks.
- Recovery from recent therapy (except for alopecia), including chemotherapy, immunotherapy, biologic therapy, or investigational product. Any such therapy must have been completed at least 3 weeks before randomization and at least 6 weeks from use of nitrosourea, or mitomycin.
- Recovery from recent surgery and radiation therapy. At least 1 week since minor surgery and/or focal/palliative radiation therapy; at least 3 weeks from radiation; at least 4 weeks from major surgery; and at least 8 weeks from liver resection, thoracotomy, or neurosurgery.
- Absolute neutrophil count ≥1500/mm^3.
- Hemoglobin ≥9 g/dL.
- Platelets ≥100,000/mm^3.
- Total bilirubin ≤1.5 times the upper limit of normal (ULN).
- Aspartate aminotransferase or alanine aminotransferase ≤2.5*ULN.
- Normal partial thromboplastin time and either international normalized ratio or prothrombin time <1.5*ULN.
- Serum creatinine ≤1.5*ULN or 24-hour creatinine clearance >60 mL/min.
- Urine dipstick for proteinuria <2+ (negative, trace, or +1). Participants with ≥2+ proteinuria at baseline were to undergo 24-hour urine collection and demonstrate ≤1g of protein in 24 hours to be eligible.
Exclusion criteria:
- Women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab.
- Women who were pregnant or breastfeeding.
- Women with a positive pregnancy test on enrollment or prior to study drug administration.
- Sexually active fertile men, whose partners were WOCBP, not using an adequate method of birth control.
- Evidence of baseline sensory or motor neuropathy.
- Serious infection or nonmalignant medical illnesses uncontrolled or the control of which could be jeopardized by this therapy.
- History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, serious gastric ulcer, or bone fracture within 6 months of study entry.
- History of hypertensive crisis or hypertensive encephalopathy.
- Significant vascular disease.
- Clinically significant cardiovascular disease.
- Baseline left ventricular ejection fraction by multiple-gated acquisition scan or echocardiogram for subjects with prior exposure to anthracyclines not within institutional normal limits.
- Symptomatic peripheral vascular disease.
- History of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within the previous 2 years.
- Evidence of bleeding diathesis or coagulopathy.
- Prior treatment with an epothilone or any antiangiogenic agent.
- Concurrent nonhealing wound, ulcer, or fracture.
- Any current or history of brain and/or leptomeningeal metastases. Psychiatric disorders or other conditions rendering the participant incapable of complying with the requirements of the protocol.
- Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix.
- Known allergy to any of the study drugs or their excipients.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
|
Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks.
Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose.
Then if still tolerated, over 30 minutes for subsequent infusions.
Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Andere Namen:
|
Experimental: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg
|
Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.)
Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks.
Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose.
Then if still tolerated, over 30 minutes for subsequent infusions.
Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Andere Namen:
|
Aktiver Komparator: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
|
Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks.
Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose.
If still tolerated, over 30 minutes for subsequent infusions.
Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study
Zeitfenster: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression
|
CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions.
|
Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression
|
Number of Participants With Best Response As Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)
Zeitfenster: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression
|
Best tumor response was assessed with RECIST.
Complete response (CR)=Disappearance of all evidence of target lesions; Partial response (PR)=At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions; Progressive disease (PD)=At least a 20% increase from baseline in the sum of LD of target lesions or the appearance of 1 or more new lesions; Stable disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
A response was confirmed if noted on 2 examinations at least 4 weeks apart.
|
Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants With Progression-free Survival at Week 24
Zeitfenster: Date of randomization to Week 24
|
Week 24 Progression-free Survival was defined as the number of participants who neither progressed nor died before Week 24.
Computed using Kaplan-Meier estimates, only at the time of Interim Analysis, when all participants had been followed for 6 months.
|
Date of randomization to Week 24
|
Median Progression-free Survival (PFS)
Zeitfenster: Date of randomization to date of progression, death, or last tumor assessment (maximum participant PFS of 29 months)
|
PFS was defined as the time from randomization to progression or to death from any cause without prior documentation of progression.
Participants who did not progress or die were to be censored on the date of their last tumor assessment.
|
Date of randomization to date of progression, death, or last tumor assessment (maximum participant PFS of 29 months)
|
Median Time to Response
Zeitfenster: Date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant time to response of 67 weeks)
|
Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for a PR or CR, whichever was recorded first.
Time to response was computed only for participants whose best response was PR or CR.
|
Date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant time to response of 67 weeks)
|
Median Duration of Response
Zeitfenster: Date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 25 weeks)
|
Duration of response was computed for participants whose best response was either PR or CR.
Duration of overall response was defined as the period from the time that measurement criteria were first met for PR or CR, whichever was recorded first, until the first date of documented PD or death.
Participants who neither relapsed nor died were to be censored on the date of their last tumor assessment.
|
Date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 25 weeks)
|
Percentage of Participants Surviving at 1 Year
Zeitfenster: Date first participant enrolled to 1 year
|
One year survival rates were computed using Kaplan-Meier estimates.
|
Date first participant enrolled to 1 year
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs) Treatment-related SAEs, Treatment-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, Treatment-related AEs
Zeitfenster: At initiation of treatment throughout study, to a minimum of 30 days after last dose of study drug
|
An AE is any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment.
An SAE is any untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization; or prolongs existing hospitalization.
Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment.
|
At initiation of treatment throughout study, to a minimum of 30 days after last dose of study drug
|
Number of Participants With Abnormalities in Hematology Laboratory Results by Worst Common Terminology Criteria (CTC) Grade
Zeitfenster: At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle
|
CTC, Version 3 used to assess parameters.
CTC Gr=Grade; WBC=white blood cells; ANC=absolute neutrophil count.
LLN=lower level of normal.
WBC Gr 1:<LLN to 3.0*10^9/L, Gr 2:<3.0 to 2.0*10^9/L, Gr 3:<2.0 to 1.0*10^9/L, Gr 4:<1.0*10^9/L;
ANC Gr 1:<LLN to 1.5*10^9/L, Gr 2:<1.5 to 1.0*10^9/L, Gr 3:<1.0 to 0.5*10^9/L, Gr 4:<0.5*10^9/L;
Platelet count Gr 1:LLN to 75.0*10^9/L, Gr 2:<75.0 to 50.0*10^9/L, Gr 3:<50.0 to 25.0*10^9/L, Gr 4:<25.0 to 10^9/L; Hemoglobin Gr 1:<LLN to 10.0 g/dL, Gr 2:<10.0 to 8.0 g/dL, Gr 3:<8.0 to 6.5 g/dL, Gr 4:<6.5 g/dL.
|
At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle
|
Number of Participants With Abnormalities in Liver Function by Worst CTC Grade
Zeitfenster: At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle
|
ULN=Upper limit of normal.ALT Gr 1:>ULN to 2.5*ULN, Gr 2: >2.5 to 5.0*ULN, Gr 3: >5.0 to 20.0*ULN, Gr 4: >20.0*ULN;
AST Gr 1: >ULN to 2.5*ULN, Gr 2: >2.5 to 5.0*ULN, Gr 3: >5.0 to 20.0*ULN, Gr 4: >20.0*ULN;
ALP Gr 1:>ULN to 2.5*ULN, Gr 2: >2.5 to 5.0*ULN, Gr 3: >5.0 to 20.0*ULN, Gr 4: >20.0*ULN;
Total bilirubin Gr 1: >ULN to 1.5*ULN, Gr 2: >1.5 to 3.0*ULN, Gr 3: >3.0 to 10.0*ULN, Gr 4: >10.0*ULN.
|
At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle
|
Number of Participants With Abnormalities in Renal Function by Worst CTC Grade
Zeitfenster: At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle
|
Creatine Gr 1: >ULN to 1.5*ULN, Gr 2: 1.5 to 3.0*ULN, Gr 3: >3.0 to 6.0*ULN, Gr 4: >6.0*ULN.
|
At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. März 2007
Primärer Abschluss (Tatsächlich)
1. November 2009
Studienabschluss (Tatsächlich)
1. November 2009
Studienanmeldedaten
Zuerst eingereicht
30. August 2006
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
30. August 2006
Zuerst gepostet (Schätzen)
31. August 2006
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
10. März 2016
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
9. Februar 2016
Zuletzt verifiziert
1. Februar 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Hautkrankheiten
- Neubildungen
- Neubildungen nach Standort
- Brusterkrankungen
- Neoplasien der Brust
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, Phytogen
- Antineoplastische Mittel, immunologische
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Paclitaxel
- Bevacizumab
- Epothilone
Andere Studien-ID-Nummern
- CA163-115
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Metastasierter Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
-
Xentria, Inc.AbgeschlossenGesunde TeilnehmerVereinigte Staaten
-
Hoffmann-La RocheAbgeschlossenDarmkrebsFrankreich, Israel, Italien, Spanien, Schweden, Hongkong, Australien, Kanada, Schweiz, Vereinigte Staaten, Irland, Dänemark, Deutschland, Taiwan, Russische Föderation, China, Neuseeland, Österreich, Vereinigtes Königreich, Ungarn und mehr
-
Keymed Biosciences Co.LtdNoch keine RekrutierungSystemischer Lupus erythematodes
-
R-PharmBeendetNeoplasien der BrustVereinigte Staaten
-
R-PharmGlaxoSmithKlineBeendetLokal fortgeschrittener oder metastasierter BrustkrebsVereinigte Staaten, Italien, Australien
-
Millennium Pharmaceuticals, Inc.AbgeschlossenMyelodysplastische Syndrome | Leukämie, myeloisch, akutJapan, Taiwan, Korea, Republik von
-
Suzhou Transcenta Therapeutics Co., Ltd.AbgeschlossenFortgeschrittene solide TumorenVereinigte Staaten
-
MedImmune LLCAbgeschlossenRezidivierende/refraktäre aggressive B-Zell-LymphomeVereinigte Staaten
-
Eisai Co., Ltd.Abgeschlossen
-
Eisai Inc.BiogenAktiv, nicht rekrutierendAlzheimer-KrankheitVereinigte Staaten, Kanada, Frankreich, Deutschland, Italien, Japan, Korea, Republik von, Niederlande, Spanien, Schweden, Vereinigtes Königreich